Media headlines about Conatus Pharmaceuticals (NASDAQ:CNAT) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Conatus Pharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.9210328597799 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Research Analysts Issue Forecasts for Conatus Pharmaceuticals Inc’s FY2022 Earnings (CNAT) (americanbankingnews.com)
- Technical note to watch on Conatus Pharmaceuticals Inc. (CNAT) – – Wall Street Morning (wallstreetmorning.com)
- Investors watching Analysts Rating of Conatus Pharmaceuticals Inc. (CNAT) – Wall Street Morning (wallstreetmorning.com)
- $9.50 Million in Sales Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarter (americanbankingnews.com)
- Conatus Pharmaceuticals to Host Expert Call on Unmet Need in HCV-SVR Patients – GlobeNewswire (press release) (globenewswire.com)
CNAT has been the subject of a number of research analyst reports. Zacks Investment Research downgraded Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, January 22nd. HC Wainwright restated a “buy” rating and set a $17.00 price objective (down from $18.00) on shares of Conatus Pharmaceuticals in a report on Thursday, November 2nd. Roth Capital initiated coverage on Conatus Pharmaceuticals in a report on Thursday, February 8th. They set a “buy” rating and a $20.00 price objective for the company. Finally, S&P Equity Research upped their price objective on Conatus Pharmaceuticals from $5.02 to $5.69 in a report on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $13.67.
ILLEGAL ACTIVITY WARNING: “Conatus Pharmaceuticals (CNAT) Earns Media Sentiment Rating of 0.17” was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.chaffeybreeze.com/2018/02/17/conatus-pharmaceuticals-cnat-earns-media-sentiment-rating-of-0-17.html.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.